Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
← catalyst calendarNCT06590090 · readout in 148 d
Sponsored by XBiotech, Inc. (industry) · XBIT — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
108estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-15 | estimated | When the study began enrolling |
| Primary completion | 2027-01-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Biological: Natrunix 400 mg — also filed as methotrexate
- Drug: Placebo
- Drug: Methotrexate (MTX)
Primary outcome
what the primary-completion date above is the date OFACR 20 response
measured at 14 weeks from baseline
Permalink · XBIT's whole pipeline · Catalyst calendar · Every registered study · What changed